Related to Abbott Pays Galapagos $150M Up Front for Phase II-Stage Rheumatoid Arthritis Drug

• Evotec Pays €10.25M for Galapagos’ Compound-Management Business
  
• Merck & Co. Teams with Hanwha to Develop Biosimilar Enbrel
  
• Alder Earns $15M Milestone from BMS on the Start of Phase IIa Trial with IL-6-Targeting mAb
  
• FDA Clears Self-Injectable Formulation of BMS’ Rheumatoid Arthritis Drug
  
• FDA Sanctions Abbott's Genetic FISH Panel for Leukemia Prognosis
  
• BMS and Ono Expand Cancer Antibody Deal and Agree to Partner Orencia in Japan
  
• Abbott to Split into Two Separate Companies
  
• Pfizer Returns Two Early-Stage Anti-TNF-Alpha Nanobodies to Ablynx
  
• FDA Clears Abbott’s Confirmatory Chagas Disease Assay
  
• Sistemic Joins €5.9M TiGenix-Led EU Consortium to Develop Stem Cell Rheumatoid Arthritis Therapy
  
• Desensitizing Chemokine Receptor Reduces Recruitment of Activated T Cells in RA
  
• Abbott Achieves CE Mark for PLEX-ID Microbial Identification Technology, Assays
  
• Abbott’s Parkinson Therapy Benefits On and Off Times in Phase III Trial
  
• Humira Anchors Abbott’s 44% Increase in Net Income This Quarter Compared to Q1 2011
  
• Novo Nordisk, Kennedy Institute Partner on Rheumatoid Arthritis Drug and Biomarker R&D
  
• Late-Stage Study Shows Benefits of Abbott's Humira Against Nonradiographic axSpA
  
• Abbott Expects Spinoff AbbVie to Be a $17.4B Proprietary Drug-CMO Powerhouse
  
• Testosterone Assay Approved in Europe
  
• New Crohn’s Disease Approval for Humira
  
• Viral Load Assay Employed for Phase III CMV Vaccine Trial